《福泰制药Vertex Pharmaceuticals（VRTX）2025年第三季度财报（10-Q）「NASDAQ」（英文版）（45页）.pdf》由会员分享，可在线阅读，更多相关《福泰制药Vertex Pharmaceuticals（VRTX）2025年第三季度财报（10-Q）「NASDAQ」（英文版）（45页）.pdf（45页珍藏版）》请在三个皮匠报告上搜索。

1、Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549_FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30,2025or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES E

2、XCHANGE ACT OF 1934FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319_Vertex Pharmaceuticals Incorporated(Exact name of registrant as specified in its charter)Massachusetts(State or other jurisdiction of incorporation or organization)50 Northern Avenue,Boston,Massachusetts(Address of

3、 principal executive offices)04-3039129(I.R.S.Employer Identification No.)02210(Zip Code)Registrants telephone number,including area code(617)341-6100_Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading SymbolName of each exchange on which registeredCommon Stock,$0.0

4、1 Par Value Per ShareVRTXThe Nasdaq Global Select MarketIndicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during thepreceding 12 months(or for such shorter period that the registrant was required t

5、o file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during th

6、e preceding 12 months(or for such shorter period that the registrant was required to submit such files).Yes No Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated filer,a smaller reporting company,or an emerging growthcompany.See the defi